$283 Million is the total value of CAXTON CORP's 25 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 60.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $192,636,000 | – | 710,100 | +100.0% | 68.07% | – |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $32,388,000 | -31.5% | 5,398,034 | +0.4% | 11.44% | -77.7% |
| MEIP | New | MEI PHARMA INC | $17,338,000 | – | 4,400,439 | +100.0% | 6.13% | – |
| Buy | GARRISON CAP INC | $9,094,000 | +0.4% | 1,118,529 | +0.3% | 3.21% | -67.3% | |
| CMFN | Buy | CM FIN INC | $7,905,000 | +19.1% | 888,220 | +9.7% | 2.79% | -61.2% |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $5,511,000 | -33.7% | 1,053,787 | +1.4% | 1.95% | -78.4% |
| SCYX | Sell | SCYNEXIS INC | $4,846,000 | -25.7% | 2,955,000 | -39.3% | 1.71% | -75.8% |
| AMLP | New | ALPS ETF TRalerian mlp | $4,233,000 | – | 419,107 | +100.0% | 1.50% | – |
| BRKB | BERKSHIRE HATHAWAY INC DELcl b new | $1,738,000 | -6.5% | 9,312 | 0.0% | 0.61% | -69.5% | |
| JBGS | JBG SMITH PPTYS | $1,501,000 | +8.1% | 41,170 | 0.0% | 0.53% | -64.8% | |
| UHAL | AMERCO | $962,000 | +3.2% | 2,700 | 0.0% | 0.34% | -66.4% | |
| PCG | PG&E CORP | $958,000 | -3.0% | 22,500 | 0.0% | 0.34% | -68.4% | |
| TPIV | New | TAPIMMUNE INC | $798,000 | – | 84,674 | +100.0% | 0.28% | – |
| GTXI | Buy | GTX INC DEL | $763,000 | -13.0% | 49,805 | +0.8% | 0.27% | -71.6% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $390,000 | +5.4% | 19,514 | -7.7% | 0.14% | -65.7% |
| ABDC | Sell | ALCENTRA CAP CORP | $354,000 | -20.6% | 55,359 | -13.7% | 0.12% | -74.2% |
| TCAP | Sell | TRIANGLE CAP CORP | $302,000 | -44.4% | 26,286 | -46.2% | 0.11% | -81.8% |
| KURA | New | KURA ONCOLOGY INC | $299,000 | – | 16,415 | +100.0% | 0.11% | – |
| Buy | INTEC PHARMA LTD JERUSALEM | $285,000 | -27.8% | 64,817 | +0.8% | 0.10% | -76.5% | |
| FPACU | New | FAR PT ACQUISITION CORPunit 06/01/2025 | $225,000 | – | 22,104 | +100.0% | 0.08% | – |
| CPRX | Sell | CATALYST PHARMACEUTICALS INC | $105,000 | +22.1% | 33,801 | -6.3% | 0.04% | -60.2% |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $103,000 | – | 48,707 | +100.0% | 0.04% | – |
| SRRA | Sell | SIERRA ONCOLOGY INC | $100,000 | +28.2% | 33,731 | -10.2% | 0.04% | -58.8% |
| MRNS | Sell | MARINUS PHARMACEUTICALS INC | $93,000 | -8.8% | 13,105 | -51.1% | 0.03% | -70.3% |
| ARQL | New | ARQULE INC | $72,000 | – | 12,959 | +100.0% | 0.02% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -13,074 | -100.0% | -0.14% | – |
| ADNT | Exit | ADIENT PLC | $0 | – | -3,838 | -100.0% | -0.25% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -1,999 | -100.0% | -0.25% | – |
| BUD | Exit | ANHEUSER BUSCH INBEV SA/NVsponsored adr | $0 | – | -4,425 | -100.0% | -0.53% | – |
| FSK | Exit | FS INVT CORP | $0 | – | -70,115 | -100.0% | -0.55% | – |
| AGRX | Exit | AGILE THERAPEUTICS INC | $0 | – | -1,814,949 | -100.0% | -5.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.